Dr. Shiva Shankar Endocrinologist in Hyderabad

Dr. Shiva Shankar

Endocrinologist, Hyderabad

MBBS, DIP, DIAB, FIDF

  • 3 Hospitals
  • Languages : English, Hindi, Telugu

Experience

Managing Director, The Hyderabad Diabetes Centre chain

Specialities

  • Endocrinology

  • Diabetology

Conditions

  • Diabetes

  • Diabetes Type 1

  • Diabetes Type 2

  • Gestational Diabetes

  • Hypertension

    • Essential (primary) hypertension

    • Arterial Hypertension

    • High blood pressure

Expertise

Education

A post-graduate Diploma in Diabetology, Vuk Vrhovac University Clinic for Diabetes, Zagreb, Croatia

ACC in Diabetology, NIMS, Hyderabad

Received special training in diabetic foot care management, Kings College Hospital, London

Practice Information

Hyderabad Diabetes Centre, Ameerpet

Hyderabad Diabetes Centre, Ameerpet

Siri Estates, Image Hospitals Lane, Near Nagarjuna Nagar , Ameerpet, Hyderabad, Telangana - 500073

SUN, MON, TUE, WED, THU, FRI, SAT

10:00 AM - 01:30 PM

Hyderabad Diabetes Centre, Kukatpally

Hyderabad Diabetes Centre, Kukatpally

KPHB Colony, # MIG-241, Kukatpally, Hyderabad, Telangana - 500072

TUE

06:30 PM - 07:30 PM

Sri Sri Holistic Hospitals, Hyderabad

Sri Sri Holistic Hospitals, Hyderabad

Hydernagar, #1 - 2 - 49/13B, Nizampet Road, Kukatpally, Hyderabad, Telangana - 500072

Achievements & Contributions

News
  • Multicentre, Open Label, Non Randomised, on International, Observational, Safety & Effectiveness Study in Subjects Using Biphasic Insulin Aspart30 (Novomix30) for Treatment of Diabetes Mellsitus. (IMPROVE  STUDY).
  • A Cross Sectional Study (IDMPS). International Diabetes Management Practice Study HOE 901/9010-2005.
  • A Cross Sectional Study (IDMPS). International Diabetes Management Practice Study HOE 901/9010-2006.
  • An Open Label, Randomised, Comparative, Multicentric Clinical Trial to Evaluate the Safety and Efficacy of Pregabalin Sustained Release Formulation Compared to Pregabalin Conventional Release Formulation in Patients of Diabetic Peripheral Naturopathic Pain. 2008.
  • EDGE Study – A Multinational, Multicentre, Post-Authorisation, Prospective Observational Cohort Study to Assess the Profile of Vildagliptin and the Fixed-dose Combination of Vildagliptin/ Metformin Relative to Comparator Oral Anti-Diabetic Drugs in Patients with Type 2 Diabetes in a Real-World Setting. 2010-11.
  • A Randomised, Double Blind, Comparative, Prospective, Multicentre, Parallel Study to Assess Efficacy, Safety and Tolerability of Fixed Dose Combination of Repaglinide / Metformin IR Tablet When Compared with Metformin IR Tablet or Repaglinide Tablet in Adult Patients with Type 2 Diabetes Mellitus. 2011.
  • Member, Diabetes and Pregnancy Study Group in India (DIPSI)
  • Member, European Association for the Study of Diabetes (EASD)
  • Member, International Diabetes Federation (IDF)
  • Member, American Diabetes Association (ADA)
  • Member, Indian Thyroid Society (ITS).
  • Member, Indian Society of Bone and Mineral Research (ISBMR)
  • Member, Research Society for the Study of Diabetes in India. (RSSDI)
  • Member, Diabetic Foot Society of India (DFSI).
-->